Company Interview Excerpt PAUL CLARK - ICOS CORPORATION (ICOS) Full article published: 9/14/2001     For Subscribers Get this article online now! Order just this article Get Financial Filings and Annual Reports for Companies featured on TWST from EasyReports.net TWST: Could we start out with a general overview and summary of your background and ICOS Corporation? Mr. Clark: ICOS is a product-driven biotech company dedicated to bringing novel and effective drugs to market that meet significant and unmet medical needs. We've spent the past decade building a highly credible and committed research and development organization, and we now are at the most exciting time in the history of the company. With three late-stage products moving steadily through the product pipeline ' and more in research and development ' ICOS is strategically poised to become a strong and successful commercial organization. It's difficult enough to get one product to pass all the hurdles to advance to late- stage human testing, and we have three. Another milestone we met in June 2001 is filing our first NDA (new drug application), along with our partner Eli Lilly, for Cialis_, a drug for treating erectile dysfunction. This takes ICOS from a research organization to a fully integrated company, which is a major step for any biotech company. I came to ICOS in June 1999 as Chief Executive Officer, and assumed the role of Chairman in February 2000. Prior to that, I was an Executive Vice President at Abbott for 14 years, responsible for three of its businesses and a member of the Board of Directors. Before Abbott, I worked at Marion Laboratories and Sandoz, which is now Novartis. So, all told, I've been in the industry now for approximately 30 years. TWST: What is the cash/capital situation at this point? Mr. Clark: We stated publicly last year that we would probably need to do one more round of financing before becoming cash flow positive. We currently have approximately 200 million in cash. We filed a 300 million shelf about a month ago, which represents about 10% of our capitalized value. We see our cash needs beyond that as being modest. Tickers included in this excerpt: ICOS Have TWST notes emailed to you free: Email address: For more information call (212) 952 7400. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.

Why TWST? Money Managers: Thousands of easy-to-read verbatim CEO interviews Must-have backgrounder before meeting with management Analyst interviews offer discurse complement to published research Roundtables 2-6 analysts discuss sector from multi-broker perspective Fellow money managers discuss investment strategy and holdings. Company Research: Peer company research Strategic planning and partnership information Find out what Wall Street is saying about your company's sector and its competitors Tool for sales and marketing teams to learn customer needs Business Schools: Unique tool for investment clubs Background for finance, securities analysis and strategic planning classes Placement resource for researching potential employers Company research Market intelligence Consultants, Bankers & Corporate Advisors: Quick background study on all major business sectors Learn about potential client needs Research tool for serving current clients Subscribe Now